A phase II study of HSP90 inhibitor AUY922 and erlotinib (E) in patients (PTS) with EGFR-mutant lung cancer and acquired resistance (AR) to EGFR tyrosine kinase inhibitors (EGFR TKIS) Meeting Abstract

  

Authors:	Yu, H. A.; Johnson, M. L.; Urman, A.; Rademaker, A.; Hart, E.; Weitner, B. B.; Patel, J. D.; Kris, M.; Riely, G.
Abstract Title:	A phase II study of HSP90 inhibitor AUY922 and erlotinib (E) in patients (PTS) with EGFR-mutant lung cancer and acquired resistance (AR) to EGFR tyrosine kinase inhibitors (EGFR TKIS)
Meeting Title:	15th World Conference on Lung Cancer (IASLC)
Keywords:	erlotinib; egfr; hsp90; acquired resistance
Journal Title:	Journal of Thoracic Oncology
Volume:	8
Issue:	Suppl. 2
Meeting Dates:	2013 Oct 27-31
Meeting Location:	Sydney, Australia
ISSN:	1556-0864
Publisher:	Elsevier Inc.
Date Published:	2013-11-01
Start Page:	S596
Language:	English
ACCESSION:	WOS:000339624902340
PROVIDER:	wos
DOI:	10.1097/01.JTO.0000438438.14562.c8
Notes:	Meeting Abstract: P1.11-008 -- Source: Wos

https://synapse.mskcc.org/synapse/works/has_related_data_chk/65651